Explore chapters and articles related to this topic
Burkholderia
Published in Dongyou Liu, Handbook of Foodborne Diseases, 2018
Danielle L. Peters, Jaclyn G. McCutcheon, Karlene H. Lynch, Jonathan J. Dennis
Because these intoxications have been limited to resource-poor areas and are relatively uncommon in comparison with many other foodborne pathogens, few detection measures for B. gladioli pv. cocovenenans have been described. B. gladioli pv. cocovenenans can be propagated on both CCM and laboratory-made tempe bongkrek.75 When toxoflavin is produced by bacteria growing on either of these growth media, the media will turn a yellow color, which is a useful diagnostic criterion.90 The differential properties of these types of media are somewhat limited because other bacteria can also produce toxoflavin and not all B. gladioli pv. cocovenenans strains produce detectable levels of toxoflavin under laboratory conditions.16,86–88,90 However, because these intoxications have such a limited range, both with respect to the geographic area and the types of food involved, bacterial growth and toxin production on CCM or laboratory-made tempe bongkrek can be useful for propagation and preliminary analysis of B. gladioli pv. cocovenenans in food outbreaks.
Burkholderia
Published in Dongyou Liu, Laboratory Models for Foodborne Infections, 2017
Danielle L. Peters, Fatima Kamal, Jonathan J. Dennis
B. gladioli pv. cocovenenans cells are motile, aerobic, non-spore-forming, nonencapsulated Gram-negative rods. These bacteria form smooth, round colonies (on potato dextrose agar) that are yellow pigmented due to the production of toxoflavin. Growth can occur between 6°C and 41°C, but is optimal between 30°C and 37°C, and toxin production occurs between 22°C and 30°C.139,140
SIRT1: a potential tumour biomarker and therapeutic target
Published in Journal of Drug Targeting, 2019
Bin Zhao, Xin Li, Liangfu Zhou, Ye Wang, Peng Shang
Lung cancer is the most common cancer and exhibits the highest mortality among all cancers worldwide [16]. It can be broadly divided into small-cell lung cancer (SCLC, 15%) and non-small-cell lung cancer (NSCLC, 85%), of which the latter includes squamous cell carcinoma, adenocarcinoma and large cell carcinoma subtypes [17,18]. Noh et al. [19] reported that positive SIRT1 expression was significantly associated with the progression and metastasis of NSCLC. Additionally, Tseng et al. [20] and Grbesa et al. [21] found that patients with high levels of SIRT1 showed a worse prognosis and higher risk of recurrence. Subsequently, growing evidence has suggested that SIRT1 might be a prognostic molecular biomarker and therapeutic target in patients with NSCLC [22,23], as well as an indicator of a poor prognosis in lung adenocarcinoma [24]. Moreover, Choi et al. [25] discovered that toxoflavin, a small-molecule SIRT1 inhibitor, exhibited significant inhibitory effects on NSCLC. Consistent with the previous reports, Fong et al. [26] suggested that the use of a sirtuin inhibitor sirtinol may inhibit human lung cancer cells. Recently, Wang et al. [27] revealed that SIRT1 was highly correlated with sensitivity in cisplatin-resistant lung adenocarcinoma cells. To date, SIRT1 is under reported in SCLC cancer and the large cell carcinoma subtype.